We can provide a complete vision of the complexities of cardiovascular disease treatments
Medicus Economics has deep experience in cardiovascular disease that spans multiple data sources and modeling strategies.
Select projects include:
- Modeled cost-effectiveness of atorvastatin for secondary prevention of cardiovascular events in an all-comers population using clinical trials data
- Analyzed claims data to quantify costs of cardiovascular sequelae of auto-immune disorders
- Led claims data analysis of health plan spending and workplace absenteeism for three types of cardiovascular interventions
- Performed electronic health records analysis of CHF outcomes in a Medicare population
- Led modeling of the cost-effectiveness of atorvastatin for primary and secondary prevention of cardiovascular events in type 2 diabetes using trials data
- Led modeling on HTA submissions for amlodipine besylate/atorvastatin calcium including publication for US private insurance audience and HTA submission to CDR (Canada)
- Assessed implications of risk equations (e.g., Framingham, SCORE) on value for cardiovascular products of a top five pharma company from an HEOR perspective
- Led cost-effectiveness modeling and analysis of price implications of an HDL-C increasing therapy (torcetrapib) in a US national private insurance setting
- Used de-identified Medicare claims from a Medicare Demonstration project to assess CHF outcomes in a Medicare population
- Directed development of US-focused microsimulation to assess value of apixaban and new oral anti-coagulants for atrial fibrillation
- Developed cost-effectiveness model assessing rivaroxaban for the treatment of venous thromboembolism
- Developed discrete-choice analysis-based pricing model for novel atrial fibrillation drug in a US national private insurance setting
- Published on cardiovascular topics in diverse publications, including JAMA, British Medical Journal, Circulation, Journal of the American College of Cardiology, Health Affairs, and Pharmacoeconomics.